Literature DB >> 14984573

Merkel cell carcinoma: a clinicopathologic study with prognostic implications.

Ryan T Mott1, Bruce R Smoller, Michael B Morgan.   

Abstract

BACKGROUND: Merkel cell carcinoma (MCC) is a frequently aggressive neuroendocrine malignancy of the skin that presents in sun-exposed areas on elderly patients. Although originally described over 30 years ago, many aspects of MCC remain to be defined. Of particular importance is the need to identify prognostic factors capable of predicting the biological behavior of these tumors. Knowledge of these factors may help in determining which patients require more aggressive treatment regimens. In this study, we examined 25 cases of MCC with an attempt to identify clinical, histopathological, or immunohistochemical features capable of predicting disease outcome.
METHODS: Features that we evaluated in each case included age, gender, race, tumor location, tumor size, depth of invasion, growth pattern, lymphocytic infiltration, mitotic activity, ulceration, necrosis, vascular invasion, and perineural invasion. In addition, we examined neural cell adhesion molecule and cytokeratin-20 expression using immunohistochemical methods.
RESULTS: We found that most patients were males (84%) with an average age of 74 years. The tumors were located on the head and neck (68%) and upper extremities (32%). Overall, 64% of the patients developed metastatic disease to regional lymph nodes or distant sites (average follow-up time of 21 months). Local recurrence was also common, occurring in 29% of the patients. The overall 1- and 2-year survival rates were 80 and 53%, respectively. Histopathological examination revealed tumors with an average size of 7.2 mm. Common features included invasion into the subcutaneous adipose tissue, solid growth pattern, tumor necrosis, and vascular and perineural invasion. Findings that had a statistically significant correlation with poor outcome included tumor size > or =5 mm (p = 0.047), invasion into the subcutaneous adipose tissue (p = 0.005), diffuse growth pattern (p = 0.040), and heavy lymphocytic infiltration (p = 0.017). The remaining findings, including the immunohistochemical results, did not correlate with disease outcome. Using logistic regression models, we show that depth of invasion and degree of lymphocytic infiltration are strong predictors of disease outcome.
CONCLUSIONS: The current controversies regarding the treatment of early-stage MCC (i.e., localized disease) underscore the importance of identifying clinicopathological features capable of predicting tumor behavior. In this study, we have identified several prognostic features in MCC. Perhaps, these features may prove useful in identifying patients who require more aggressive treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984573     DOI: 10.1111/j.0303-6987.2004.00149.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  22 in total

Review 1.  Merkel cell carcinoma: what do we know about it and what should we do?

Authors:  Isabel Prieto Muñoz; José Pardo Masferrer; Jesús Olivera Vegas; José Ramón Fortes Alen; Ana M Pérez Casas
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

2.  Tumor vascularization and clinicopathologic parameters as prognostic factors in merkel cell carcinoma.

Authors:  A Bob; F Nielen; J Krediet; J Schmitter; D Freundt; D Terhorst; J Röwert-Huber; J Kanitakis; E Stockfleth; Ch Ulrich; M Weichenthal; F Egberts; B Lange-Asschenfeldt
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-21       Impact factor: 4.553

3.  Digital Merkel cell carcinoma.

Authors:  Alanna M Rebecca; Randall O Craft; Anthony A Smith
Journal:  Can J Plast Surg       Date:  2005

4.  Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma.

Authors:  Samuel A Henderson; Michael T Tetzlaff; Penvadee Pattanaprichakul; Patricia Fox; Carlos A Torres-Cabala; Roland L Bassett; Victor G Prieto; Hunter W Richards; Jonathan L Curry
Journal:  J Cutan Pathol       Date:  2014-10-28       Impact factor: 1.587

5.  [A 73-year-old female patient after liver and kidney transplantation with dull pain in the epigastrium and recurrent epistaxis].

Authors:  M E Zinser; H J F Salzer; A Stein; M von Petersdorff; A Koops; J Holzhüter
Journal:  Internist (Berl)       Date:  2015-05       Impact factor: 0.743

6.  Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.

Authors:  Laurence Feldmeyer; Courtney W Hudgens; Genevieve Ray-Lyons; Priyadharsini Nagarajan; Phyu P Aung; Jonathan L Curry; Carlos A Torres-Cabala; Barbara Mino; Jaime Rodriguez-Canales; Alexandre Reuben; Pei-Ling Chen; Jennifer S Ko; Steven D Billings; Roland L Bassett; Ignacio I Wistuba; Zachary A Cooper; Victor G Prieto; Jennifer A Wargo; Michael T Tetzlaff
Journal:  Clin Cancer Res       Date:  2016-05-10       Impact factor: 12.531

7.  Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma.

Authors:  Benjamin Lok; Sabrina Khan; Robert Mutter; Jeffrey Liu; Ryan Fields; Melissa Pulitzer; Weiji Shi; Zhigang Zhang; Dennis Kraus; David Pfister; Klaus J Busam; Isaac Brownell; Nancy Lee
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

8.  Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma.

Authors:  Melissa P Pulitzer; A Rose Brannon; Michael F Berger; Peter Louis; Sasinya N Scott; Achim A Jungbluth; Daniel G Coit; Isaac Brownell; Klaus J Busam
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

9.  Patients with Merkel cell carcinoma tumors < or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis.

Authors:  Jayme B Stokes; Katherine S Graw; Lynn T Dengel; Brian R Swenson; Todd W Bauer; Craig L Slingluff; Elihu J Ledesma
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

10.  Merkel cell tumor of the skin treated with localized radiotherapy: are widely negative margins required?

Authors:  Mark Trombetta; Matthew Packard; Claudia Velosa; Jan Silverman; Day Werts; David Parda
Journal:  Rare Tumors       Date:  2011-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.